A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation.

[1]  S. H. van der Burg,et al.  Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. , 1996, Journal of immunology.

[2]  P. Cresswell,et al.  The protease inhibitor, N-acetyl-L-leucyl-L-leucyl-leucyl-L- norleucinal, decreases the pool of major histocompatibility complex class I-binding peptides and inhibits peptide trimming in the endoplasmic reticulum , 1996, The Journal of experimental medicine.

[3]  M. Bogyo,et al.  The Human Cytomegalovirus US11 Gene Product Dislocates MHC Class I Heavy Chains from the Endoplasmic Reticulum to the Cytosol , 1996, Cell.

[4]  P. Kloetzel,et al.  The cleavage preference of the proteasome governs the yield of antigenic peptides , 1995, The Journal of experimental medicine.

[5]  P. Kloetzel,et al.  The Interferon-γ-inducible 11 S Regulator (PA28) and the LMP2/LMP7 Subunits Govern the Peptide Production by the 20 S Proteasome in Vitro(*) , 1995, The Journal of Biological Chemistry.

[6]  R. Huber,et al.  Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. , 1995, Science.

[7]  T. Elliott,et al.  Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum , 1995, The Journal of experimental medicine.

[8]  K Eichmann,et al.  Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. , 1995, Immunity.

[9]  M. Feltkamp,et al.  Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. , 1995, Journal of immunology.

[10]  C. Melief,et al.  Cloning of the MCF1233 murine leukemia virus and identification of sequences involved in viral tropism, oncogenicity and T cell epitope formation. , 1994, Virus research.

[11]  J. Yewdell,et al.  Trimming of antigenic peptides in an early secretory compartment , 1994, The Journal of experimental medicine.

[12]  J. Neefjes,et al.  Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling , 1994, The Journal of experimental medicine.

[13]  Aaron Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway , 1994, Cell.

[14]  S. Tonegawa,et al.  Altered peptidase and viral-specific T cell response in LMP2 mutant mice. , 1994, Immunity.

[15]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[16]  M. Ressing,et al.  Identification of an H-2 Kb-presented Moloney murine leukemia virus cytotoxic T-lymphocyte epitope that displays enhanced recognition in H-2 Db mutant bm13 mice , 1994, Journal of virology.

[17]  K. Rajewsky,et al.  MHC class I expression in mice lacking the proteasome subunit LMP-7. , 1994, Science.

[18]  J. Neefjes,et al.  Peptide size selection by the major histocompatibility complex-encoded peptide transporter , 1994, The Journal of experimental medicine.

[19]  Clive A. Slaughter,et al.  Proteolytic Processing of Ovalbumin and β-galactosidase by the Proteasome to Yield Antigenic Peptides , 1994 .

[20]  V. Levitsky,et al.  T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues , 1994, The Journal of experimental medicine.

[21]  P M Kloetzel,et al.  Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes , 1994, The Journal of experimental medicine.

[22]  Günter J. Hämmerling,et al.  Selectivity of MHC-encoded peptide transporters from human, mouse and rat , 1994, Nature.

[23]  S. Tonegawa,et al.  Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator , 1994, The Journal of experimental medicine.

[24]  H. White,et al.  An immunodominant Kb-restricted peptide from the p15E transmembrane protein of endogenous ecotropic murine leukemia virus (MuLV) AKR623 that restores susceptibility of a tumor line to anti-AKR/Gross MuLV cytotoxic T lymphocytes , 1994, Journal of virology.

[25]  P. J. van den Elsen,et al.  Immunodominant mink cell focus-inducing murine leukemia virus (MuLV)-encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV-type specificity of MCF-directed cytotoxic T lymphocytes. , 1994, Journal of immunology.

[26]  P. Cresswell,et al.  Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manner. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Howard,et al.  Peptides and the proteasome , 1993, Nature.

[28]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[29]  S. Tonegawa,et al.  TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective , 1993, Cell.

[30]  J. Neefjes,et al.  Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. , 1993, Science.

[31]  P. J. van den Elsen,et al.  Differential usage of T cell receptor V gene segments in CD4+ and CD8+ subsets of T lymphocytes in monozygotic twins. , 1993, Journal of immunology.

[32]  M Orlowski,et al.  Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. , 1993, Biochemistry.

[33]  A. Osterhaus,et al.  Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition , 1992, The Journal of experimental medicine.

[34]  A. Goldberg,et al.  Proteolysis, proteasomes and antigen presentation , 1992, Nature.

[35]  C. Anderson.  Less science, more policy at Amsterdam AIDS meeting , 1992, Nature.

[36]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[37]  U. Koszinowski,et al.  Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein , 1991, Cell.

[38]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[39]  M. Zijlstra,et al.  Major histocompatibility complex class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas , 1988, Journal of virology.

[40]  D. Brahams.  Human immunodeficiency virus and the law. , 1987, Lancet.

[41]  M. Zijlstra,et al.  Virology, genetics and immunology of murine lymphomagenesis. , 1986, Biochimica et biophysica acta.

[42]  H. Ljunggren,et al.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism , 1985, The Journal of experimental medicine.

[43]  M. Zijlstra,et al.  Naturally occurring leukemia viruses in H-2 congenic C57BL mice. III. Characterization of C-type viruses isolated from lymphomas induced by milk transmission of B-ecotropic virus. , 1983, Virology.

[44]  R. Lerner,et al.  Nucleotide sequence of Moloney murine leukaemia virus , 1981, Nature.

[45]  K. Ozato,et al.  Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression. , 1981, Journal of immunology.

[46]  F. Plata,et al.  Viral specificity of H-2-restricted T killer cells directed against syngeneic tumors induced by Gross, Friend, or Rauscher leukemia virus , 1979, The Journal of experimental medicine.

[47]  C. Melief,et al.  Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. , 1992, Advances in cancer research.